Finkelstein Thompson LLP Announces Investigation Of Affymax, Inc.

WASHINGTON--(BUSINESS WIRE)--The law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Affymax, Inc. (“Affymax” or “the Company”) (Nasdaq: AFFY). Finkelstein Thompson’s investigation relates to the recent announcement by Affymax and partner Takeda Pharmaceutical that they were voluntarily recalling all lots of Omontys, Affymax’s flagship anemia drug.